Press Releases
February 26, 2018

Data on Lead Program SYNT001 to be Presented at Plenary Session of International Investigative Dermatology Conference

WALTHAM, Mass., February 26, 2018–(BUSINESS WIRE)– Syntimmune, Inc., a clinical-stage biotechnology company focused on FcRn biology, today announced that SYNT001 data will be presented at a plenary session at the International Investigative Dermatology (IID) Conference at 10:15 am ET on May 17, 2018, in Orlando, Florida. During the session, an investigator will present initial data from the ongoing Phase 1b, multicenter, open-label, safety, tolerability, and activity study of SYNT001 in patients with the autoimmune disease pemphigus. The first-in-human study in pemphigus is designed to provide initial clinical proof-of-concept for anti-FcRn treatment with SYNT001 in this disorder.

“We look forward to sharing initial data from our lead program targeting FcRn during the plenary session at the IID, one of the premier academic forums for investigative dermatology,” said Jean-Paul Kress, M.D. President and CEO of Syntimmune. “As a powerful modulator of Ig-G driven immune responses, SYNT001 offers a compelling opportunity for therapeutic intervention in the field of autoimmunity. As a leader in FcRN-targeted clinical development, we welcome the opportunity to share our initial clinical data with the community.”

About Syntimmune

Founded in 2013, Syntimmune is advancing novel therapies based on its leading position in the biology of the neonatal Fc receptor (FcRn). Based upon preclinical models, FcRn functions as a core part of a central common pathway that enables abnormal IgG responses, making it a well-validated target for the treatment of IgG-mediated autoimmune diseases. Syntimmune’s lead candidate, SYNT001, is a monoclonal antibody that specifically blocks FcRn-IgG interactions and is being studied in multiple Phase 1b/2a trials for the treatment of IgG-mediated autoimmune diseases. In addition to SYNT001, Syntimmune is developing SYNT002, which targets the interaction between FcRn and albumin and promotes clearance of albumin-bound endo- and exotoxins. The Syntimmune team has world-class experience in the field of FcRn biology and has successfully pioneered and advanced biologics that engage FcRn. Since its founding, the company has been funded with a total of $78 million in capital commitments from leading life sciences investors, led by Apple Tree Partners and includes Partners Innovation Fund, FMB Research, and AFB Fund. For more information on Syntimmune, please visit the company’s website at

Media Contact:
Dan Quinn
Ten Bridge Communications

Your browser is out-of-date!

Update your browser to view this website correctly.Update my browser now